grant
Increasing the protective capacity of antibodies by enhancing Fc-mediated responses
Organization UNIVERSITY OF GEORGIALocation ATHENS, UNITED STATESPosted 5 May 2025Deadline 30 Apr 2030
NIHUS FederalResearch GrantFY20267S Gamma GlobulinAb-dependent cellular cytotoxicityAb-mediated immunityAb-mediated protectionAffectAffinityAmino Acid SubstitutionAntibodiesAntibody RepertoireAntibody TherapyAntibody immunityAntibody protectionAntibody-mediated protectionAntigenic DeterminantsBacteriaBindingBinding DeterminantsCarbohydratesCell BodyCell surfaceCellsClinical Treatment MoabComplementComplement ProteinsComplement-Dependent CytotoxicityComplexCytotoxic cellD pneumoniaeD. pneumoniaeDNA mutationDeoxygalactoseDepositDepositionDiplococcus pneumoniaeEffector CellEpitopesFucoseFutureGenetic ChangeGenetic defectGenetic mutationGlycansGoalsGrippeHumanHuman FigureHuman bodyIgGIgG ReceptorsIgG1ImmuneImmune responseImmunesImmunizationImmunoglobulin GImmunoglobulin G ReceptorIn VitroIndividualInfectionInferiorInfluenzaInfluenza VirusK lymphocyteKnowledgeLaboratoriesLibrariesLocationMediatingMetabolic GlycosylationMethodsMiceMice MammalsModelingModern ManMolecular InteractionMonoclonal AntibodiesMonoclonal Antibody TherapyMurineMusMutationNK CellsNatural Killer CellsPatientsPersonsPhagocytosisPneumococcusPolysaccharidesPropertyProteinsReceptor ProteinS pneumoniaeS. pneumoniaeSiteStreptococcus pneumoniaeTherapeuticVaccinesVirusalpha-Fucoseanti-microbialantibody based therapiesantibody dependent cell mediated cytotoxicityantibody dependent cytotoxicityantibody librariesantibody mediated cellular cytotoxicityantibody treatmentantibody-based therapeuticsantibody-based treatmentantibody-dependent cell cytotoxicityantibody-dependent cellular cytotoxicityantibody-mediated cytotoxicityantibody-mediated immunityantimicrobialbacteria pathogenbacterial pathogencomplement-mediated cytotoxicitycomplementationdefined contributiondesigndesigningdevelop a vaccinedevelop vaccinesdevelopment of a vaccineexpectationexperimentexperimental researchexperimental studyexperimentsflu infectionflu virus infectiongamma Fc Receptorsgenome mutationglycosylationhost responseimmune system responseimmunoresponseimprovedin vivoinfected with fluinfected with flu virusinfected with influenzainfected with influenza virusinfluenza infectioninfluenza virus infectioninfluenzavirusintravenous administrationmAB-based therapymAb therapymAb-based therapeuticsmAbsmicrobe pathogenmicrobial pathogenmonoclonal Absmouse modelmurine modelneutralizing antibodyneutralizing mAbneutralizing monoclonal antibodiesnovelpathogenpathogenic bacteriapathogenic microbepathogenic viruspreventpreventingreceptorresponsesuccesssynergismtoolvaccine developmentvaccine efficacyvaccine failurevaccine responsevaccine responsivenessvaccine-induced responseviral pathogenvirus pathogen
Description preview
Project Summary
Vaccines are powerful tools against microbial pathogens; however, it has not been possible to elicit antibodies
that neutralize each pathogen nor to generate sufficient neutralizing antibodies in each person. Along with
neutralizing antibodies, vaccines and infection often generate non-neutralizing antibodies that can provide…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click